This program is developing and testing a new antibiotic therapy for cystic fibrosis. This therapy is a combination of two existing approved drugs: the antibiotic tobramycin and another compound, calcium EDTA. When bacteria infect the lungs of people with CF, they can form structures called biofilms. Biofilms make bacteria more resistant to antibiotics. The compound calcium EDTA may help break down biofilms in the lungs, allowing antibiotics to fight bacteria more effectively.
Laboratory studies to develop and test this compound are underway.
This program is sponsored by Respirion Pharmaceuticals and partially funded by the Cystic Fibrosis Foundation.
Contact us about Respirion Pharmaceuticals >